Back to top
more

Surface Oncology, Inc. (SURF)

(Delayed Data from NSDQ)

$4.87 USD

4.87
37,567

+0.02 (0.41%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Walgreens (WBA) to Report Q2 Earnings: What's in the Cards?

Walgreens' (WBA) strategic executions on the United States and the international front is likely to have contributed to the Q2 2023 top line.

Lantheus Holdings (LNTH) Q4 Earnings and Revenues Surpass Estimates

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 42.71% and 7.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Envista (NVST) Surpasses Q4 Earnings and Revenue Estimates

Envista (NVST) delivered earnings and revenue surprises of 6.12% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Why Surface Oncology (SURF) Might Surprise This Earnings Season

Surface Oncology (SURF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Surface Oncology, Inc. (SURF) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Perrigo (PRGO) Beats Q4 Earnings and Revenue Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Q3 Earnings Top Estimates

Medtronic (MDT) delivered earnings and revenue surprises of 0.74% and 1.60%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for September 13th

AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.

Implied Volatility Surging for Surface Oncology (SURF) Stock Options

Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.

Surface Oncology, Inc. (SURF) Q4 Earnings and Revenues Beat Estimates

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 345.71% and 3.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Surface Oncology (SURF) is Oversold: Can It Recover?

Surface Oncology (SURF) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Should You Buy Surface Oncology (SURF) Ahead of Earnings?

Surface Oncology (SURF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Surface Oncology, Inc. (SURF) to Report Q4 Results: Wall Street Expects Earnings Growth

Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cooper Companies (COO) to Post Q1 Earnings: What's in Store?

Cooper Companies' (COO) fiscal first-quarter results are likely to reflect strength at MiSight 1-day contact lens.

What's in Store for Patterson Companies' (PDCO) Q3 Earnings?

Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect improvement at Dental segment.

Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?

Veeva Systems' (VEEV) fiscal fourth-quarter results are likely to reflect solid show by its segments and robust product portfolio.

ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Rise

ResMed (RMD) reported second-quarter fiscal 2021 revenues of $800 million, up 9% from a year ago.

Allscripts (MDRX) Extends Tie-Up With US Orthopedic Alliance

Allscripts (MDRX) extends strategic partnership with US Orthopedic Alliance to form a more scalable orhopedic services technology platform.

Are Options Traders Betting on a Big Move in Surface Oncology (SURF) Stock?

Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.

Earnings Estimates Moving Higher for Surface Oncology, Inc. (SURF): Time to Buy?

Surface Oncology, Inc. (SURF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks.com featured highlights include: Matson, Surface Oncology, Green Brick Partners, Merchants Bancorp and Herc Holdings

Zacks.com featured highlights include: Matson, Surface Oncology, Green Brick Partners, Merchants Bancorp and Herc Holdings

Nalak Das headshot

5 Stocks With Recent Price Strength Under Severe Volatility

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks.com featured highlights include: Daqo, Surface Oncology, Covenant, Herc and Castle Biosciences

Zacks.com featured highlights include: Daqo, Surface Oncology, Covenant, Herc and Castle Biosciences

Nalak Das headshot

5 Stocks With Recent Price Strength to Maximize Your Gains

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.